[HTML][HTML] Timely referral for device-aided therapy in Parkinson's disease. Development of a screening tool

…, AT Portman, B van Harten, ME van Kesteren… - Parkinsonism & Related …, 2023 - Elsevier
Background Timely referral of Parkinson's disease (PD) patients to specialized centers for
treatment with device-aided therapies (DAT) is suboptimal. Objective To develop a screening …

The Effect of a Structured Medication Review on Quality of Life in Parkinson's Disease

…, HW Nijmeijer, ME Van Kesteren… - Journal of …, 2022 - content.iospress.com
Background: Drug therapy is important for controlling symptoms in Parkinson’s disease (PD).
However, it often results in complex medication regimens and could easily lead to drug …

Rivastigmine for minor visual hallucinations in Parkinson's disease: a randomized controlled trial with 24 months follow‐up

…, M Kuijf, T van Laar, M van Kesteren… - Brain and …, 2021 - Wiley Online Library
Background Visual hallucinations are common in patients with Parkinson's disease and
represent probably the major independent predictor for cognitive deterioration and nursing …

The impact of non-dopaminergic medication on quality of life in Parkinson's disease

…, HW Nijmeijer, ME van Kesteren… - Clinical Drug …, 2021 - Springer
Background and Objectives Quality of life (QoL) in Parkinson’s disease (PD) depends on
multiple factors. Due to PD treatment and accompanying, age-related or independent …

Cycling is less affected than walking in freezers of gait

AH Snijders, M van Kesteren, BR Bloem - Journal of Neurology …, 2012 - jnnp.bmj.com
… Egeler RM, Favara BE, van MM, et al. Differential in situ cytokine profiles of Langerhans-like
cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant …

Timely referral for advanced therapy in Parkinson's disease. Development of a screening tool

…, AT Portman, B van Harten, ME van Kesteren… - medRxiv, 2021 - medrxiv.org
Objectives To develop a screening tool for timely referral for advanced therapy (AT) in
patients with Parkinson’s disease (PD), and to compare the newly-developed tool with the …

Deregulation of Cancer-Related Pathways in Primary Hepatocytes Derived from DNA Repair-Deficient Xpa−/−p53+/− Mice upon Exposure to Benzo[a]pyrene

PCE van Kesteren, PE Zwart, JLA Pennings… - Toxicological …, 2011 - academic.oup.com
… Petra CE van Kesteren , Petra CE van Kesteren … A selected set of genes being part of
cluster E in Figure 5 is shown, of which the expression levels were determined by microarray …

Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: long-term outcomes of a randomised trial

…, T Schukken, FHMP Tummers, PJM van Kesteren… - Gynecologic …, 2022 - Elsevier
… Kraayenbrink g , Mirjam JA Apperloo h , Brigitte Slangen i , Tineke Schukken j , Fokkedien
HMP Tummers k , Paul JM van Kesteren l , Judith AF Huirne m , Dieuwke Boskamp n , Gerton …

[HTML][HTML] Parkinson Kinetic Graph: Are Motor Fluctuations in Parkinson Disease Related with Disease Duration?

…, B Van Harten, M Van Kesteren-Biegstraaten… - Advances in Parkinson's …, 2018 - scirp.org
Introduction: The Parkinson’s KinetiGraph (PKG) is a digital measurement system for motor
fluctuations (FS). The aim of this study is to investigate whether FS, measured by the PKG, …

DNA repair-deficient Xpa / p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from …

PCE van Kesteren, RB Beems, M Luijten… - …, 2009 - academic.oup.com
… Petra CE van Kesteren , Petra CE van Kesteren … The first of two short-term carcinogenicity
studies were described previously by van Kreijl et al. ( 5 ). In short, groups of 15 male and 15 …